Literature DB >> 30855179

Impact of selective serotonin reuptake inhibitors in the veteran population: 10-year risk outcomes.

Daniel L Brinton1,2, Annie N Simpson1,3, Cory E Fominaya4, Amanda C LaRue2,5.   

Abstract

AIM: To evaluate the comparative risk of hip fracture or osteoporosis among US Veterans based on selective serotonin reuptake inhibitor (SSRI) exposure. PATIENTS &
METHODS: A retrospective cohort study of eligible US Veterans Health Administration patients enrolled in 2003-2004 was performed to examine SSRIs' 2-, 5- and 10-year impact on bone health using multiple logistic regression.
RESULTS: Veterans on SSRIs were found to be 56.7% more likely over a 10-year period to suffer a hip fracture (risk ratio: 1.567; 95% CI: 1.464-1.676) and 34.6% more likely to develop osteoporosis (risk ratio: 1.346; 95% CI: 1.319-1.374) when compared with those who were SSRI naive.
CONCLUSION: SSRI usage was associated with greater risk of hip fracture and osteoporosis over a 10-year period in the veteran population, with similar effect sizes to smaller studies.

Entities:  

Keywords:  SSRIs; citalopram; comparative risk; escitalopram; fluoxetine; fluvoxamine; fracture risk; paroxetine; risk factor; sertraline

Mesh:

Substances:

Year:  2019        PMID: 30855179     DOI: 10.2217/cer-2018-0085

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  2 in total

Review 1.  Antidepressants and Vertebral and Hip Risk Fracture: An Updated Systematic Review and Meta-Analysis.

Authors:  Renato de Filippis; Michele Mercurio; Giovanna Spina; Pasquale De Fazio; Cristina Segura-Garcia; Filippo Familiari; Giorgio Gasparini; Olimpio Galasso
Journal:  Healthcare (Basel)       Date:  2022-04-26

2.  Decreased bone mineral density in ovariectomized mice is ameliorated after subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine.

Authors:  Yuko Fujita; Kenji Hashimoto
Journal:  Neuropsychopharmacol Rep       Date:  2020-08-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.